In humans, GH receptor loss-of-function mutations (e.g., Laron syndrome) also manifest as MASLD, with chronic IGF-I replacement not affecting MASLD status, suggesting GH’s direct role in preventing steatosis in hepatocytes [27] (Figure 3). This evidence concerns the gene GH1 and steatosis.